Prelude Therapeutics Incorporated Common Stock (PRLD) Stock
NASDAQ · PRLD
4.87
Fundamentals
Market cap
$388.64M
Price / Earnings ratio
-6.0x
Price / Sales ratio
16.3x
Price / Book ratio
2.7x
Return on assets
-0.7%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Prelude Therapeutics Incorporated Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees79
CEODr. Krishna Vaddi D.V.M., Ph.D.
IPO DateSep 25, 2020
HeadquartersWilmington, DE
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Krishna Vaddi D.V.M., Ph.D. | Founder, CEO & Director | 1966 |
| Mr. Bryant David Lim J.D. | CFO, Chief Legal Officer & Corporate Secretary | 1971 |
| Dr. Peggy A. Scherle Ph.D. | Chief Scientific Officer | 1962 |
| Ms. Aimee Crombie Ph.D. | Senior VP and Head of Strategic Planning & Operations | — |
| Dr. Madhu Pudipeddi Ph.D. | Senior Vice President of Technical Operations | — |
| Mr. Robert A. Doody Jr. | Senior Vice President of Investor Relations | — |
| Ms. Michele Porreca M.B.A. | Chief People Officer | — |
| Dr. Andrew P. Combs Ph.D. | Executive VP & Chief Chemistry Officer | 1967 |
| Mr. Naveen Babbar Ph.D. | Senior Vice President of Translation Medicine | — |
| Dr. Wan-Jen Hong M.D. | Senior Vice President of Clinical Development | 1979 |
Fundamentals
Valuation
Market cap$388.64M
Price-to-sales ratio16.26
Price-to-book value2.73
Price-earnings ratio-6.00
Return on Equity-118.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.73
Income Statement
Average volume530,063
EBITDA$-74.59M
1 year high (52w)$6.83
1 year low (52w)$0.98
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



